Study of correlation of ER, PR, HER2 receptor status in breast cancer at a single tertiary care hospital with emphasis on clinical utility of PR receptor

Anjika Shukla, Poonam Singh, Anju Shukla, Prateek Kumar Mehrotra, Farah Arshad, Priyanka Jain


Background: The receptor status of breast cancer, including ER, PR and HER 2, play a crucial role in the development of treatment plan of breast cancer. Clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well established, added value of PR is less defined. This study aim to know the demography of breast cancer and to document the status of ER, PR and HER 2 status in the north Indian population, as catered by single tertiary care hospital in Lucknow, Uttar Pradesh.

Methods: All the patients of breast cancers where surgery or core biopsy was performed for invasive breast carcinoma followed by evaluation of ER, PR and HER 2 status were included in the study from January 2014 to June 2018. Cases were analyzed retrospectively for documentation of ER, PR and HER2 status, using American society of Clinical Oncology/College of American Pathologists (ASCO/CAP) interpretation guidelines.

Results: 112 patients were included in the study with mean age of 53.70±12.47. Most common histological type was invasive carcinoma of no special type. 43.75% cases were ER+/PR+, 5.35% were ER+/PR-, and 50.89% were ER-/PR-. ER-/PR+ status was seen in none of our cases. Correlation of ER and PR with HER 2 was possible in 90 cases and triple negative breast cancer (TNBC) status was observed in 32.2% of cases.

Conclusions: Demography and ER positivity and incidence of TNBC is not different from rest of India, however the clinical utility for evaluation of PR receptor is to be further investigated.


Breast carcinoma, Estrogen, Progesterone, HER 2 receptor

Full Text:



Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017;13(4):289-95.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-95.

Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype Breast Cancer Res. 2013;15(4):68.

Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al:Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol. 2004;22:1769-70.

Stewart BW, Wild CP. In:Bernard W.Stewart, Christopher P.Wild eds. World cancer report 2014.

Chopra B, Kaur V, Singh K, Verma M, Singh S, Singh A. Age shift:Breast cancer is occurring in younger age groups-is it true? Clin Cancer Investig J. 2014;3:526-9.

Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J cancer. 2010;47(1):16-22.

Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):6.

Harvey JM, Clark GM, Osbome CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-84.

Horii R, Akiyama F, Ito Y, Iwase T. Assessment of hormone receptor status in breast cancer. Pathol Int. 2007;57:784–90.

Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India:a study of 798 tumours.Breast.2000;9(5):267-70.

Suvarchala SB, Nageswararao R. Carcinoma breast-Histopathological and hormone receptors correlation. J Biosci Tec. 2011;2:340-8.

Mudduwa LK. Quick score of hormone receptor status of breast carcinoma:Correlation with the other clinicopathological prognostic parameters. Indian J Pathol Microbiol. 2009;52:159–63.

Chatterjee K, Bhaumik G, Chattopadhyay B. Estrogen receptor and progesterone receptor status of breast cancer patients of eastern India: A multi-institutional study. South Asian J Cancer. 2018;7(1):5–6.

Kaul R, Sharma J, Minhas SS, Mardi K. Hormone receptor status of breast cancer in the himalayan region of northern India. Indian J Surg. 2011;73(1):9-12.

Dowsett M, Cuzick J, Wale C, Howell T, Howell T, Houghton J, Baum M, Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status :an hypothesis –generating study. J Clin Oncol. 2005;23:7512-7.

Yao N, Song Z, Wang X, Yang S, Song H. Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients. J Breast Cancer. 2017;20(2):160–9.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.

Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Venkatesh B, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients:A tertiary care center experience. Indian J Med Paediatr Oncol. 2015;36(2):117–22.

Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of Triple-Negative Breast Cancer in India:Systematic Review and Meta-Analysis. J Glob Oncol. 2016;2(6):412–21.